Comparison of DWI-MRI and 18F-FDG PET/CT whole body scans in the diagnosis of tumors

Comparison of the efficacy of DWI-MRI and 18F-FDG PET/CT whole body scans in the diagnosis of tumors: a multicenter clinical study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN72560777

Enrollment

150

Registered

2012-09-05

Start date

2012-08-30

Completion date

Unknown

Last updated

2017-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain, lung, liver and pancreatic tumor including T, N and M staging. Cancer Malignant neoplasms of ill-defined, secondary and unspecified sites

Interventions

Injection FDG accoring to mCi/KG. The research focus is to find DWI-MR and FDG PET/CT, as well as how to play their respective advantages in clinical.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Brain, lung, liver and pancreatic tumor including T, N and M staging. 1. Age of 18 - 80 years 2. Clinical pathology in patients with brain, lung, liver and pancreaticcancer 3. Patients without radiotherapy, chemotherapy 4. DWI and 18F-FDG PET/CT scanning in the same week 5. DWI and 18F-FDG PET/CT scanning sequence is random 6. Volunteered to participate in and signed informed consent

Exclusion criteria

Exclusion criteria: 1. Withdrawal of informed consent 2. Without pathology result 3. Against research programme

Design outcomes

Primary

Measure	Time frame
1. 18F-FDG PET/CT: the number of lesion, SUV 2. DWI-MRI: the number of lesion, ADC	—

Secondary

Measure	Time frame
1. 18F-FDG PET/CT: tumor volume, TLG (suv evolume) 2. DWI-MRI: tumor volume and size (max long axial)	—

Countries

China

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026